Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the trea…
$49.60+1.49%
报价 2026-11-06
市值
$4.76B
EV
$6.34B
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -26.5%
$26.79$67.52
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
爆发潜力
2026-11-07不在筛选范围：industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| TVTXTravere Therapeutics, Inc. | $4.76B | +1.5% | +40.1% | 94.4% | – | 4103.2x | 705.8x | |
| CGONCG Oncology, Inc. Common stock | $6.74B | +17.3% | +378.6% | -102.2% | – | – | – | |
| LEGNLegend Biotech Corporation | $4.33B | +3.8% | +39.4% | 55% | – | – | – | |
| XENEXenon Pharmaceuticals Inc. | $3.79B | +4.0% | – | 0% | – | – | – | |
| TARSTarsus Pharmaceuticals, Inc. | $3.38B | +1.6% | +56.4% | 90.6% | – | – | 63.5x | |
| CELCCelcuity Inc. | $3.27B | +4.3% | +4666.7% | 0% | – | – | – | |
| IRONDisc Medicine, Inc. | $3.03B | +0.6% | -47.5% | 0% | – | – | – | |
| RAREUltragenyx Pharmaceutical Inc. | $1.52B | -0.9% | +11.6% | 83.1% | – | – | – | |
| AAPGASCENTAGE PHARMA GROUP INTERNATIONAL | $1.43B | +2.0% | – | 81.6% | – | – | – | |
| 同行中位数 | – | – | +47.9% | 27.5% | – | – | 63.5x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。